Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
It is very uncertain whether mechanical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether mechanical thrombectomy changes minor adverse events compared with pulse spray technique (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether continuous Infusion changes minor adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes minor adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes major adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether surgical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
The review found no eligible studies for this question.
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).